Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy

KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE: SGP) Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability. TRA showed no increase in major and minor Thrombolysis in Myocardial Infarction (TIMI)-scale bleeding when given with current standard antiplatelet therapy (aspirin and clopidogrel) for patients undergoing percutaneous coronary intervention (PCI), commonly known as balloon angioplasty with stenting.

"The results of this study are encouraging as they support the viability of TRA as a potential new antiplatelet therapy option," said Richard Becker, MD, director of the Duke Cardiovascular Thrombosis Center and lead author of the study. "TRA appears to work in a novel way that is complementary to current antiplatelet therapies," he further commented.

Another important result from the Thrombin Receptor Antagonist Percutaneous Coronary Intervention (TRA-PCI) trial was the rate of thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation inhibition, a secondary endpoint. Thrombin is the most potent platelet activator, which leads to platelet aggregation and the development of blood clots. In the study, TRA showed a much higher TRAP-induced platelet aggregation inhibition compared to standard of care alone in both loading and maintenance doses.

"In this study, TRA, when given with aspirin and clopidogrel, was able to inhibit the aggregation of platelets even when
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... been appointed to the Board of Directors, effective July ... II Director until the 2018 annual meeting or until ... McDougal has served in an executive capacity in the ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... Pfizer (NYSE: PFE ) today ... Inc., a privately held drug discovery and clinical development ... a wholly owned subsidiary of Pfizer Inc.   ... Pfizer Inc: Working together for a healthier ...
... Baxano, Inc. ( www.baxano.com ) today announced that two of ... Spine Care at the 2010 Spine Technology Awards. The iO-Flex™ ... in the Best New Technology in Lumbar Care. ... Technology Awards Gala in Orlando, FL. Baxano, Inc. was awarded ...
Cached Medicine Technology:Baxano, Inc. Awarded Prestigious 2010 Spine Technology Awards 2
(Date:8/3/2015)... ... August 03, 2015 , ... As reported in ... Lifetime reality series, “Atlanta Plastic” is getting attention for moving outside traditional ethnic ... its predominantly African-American cast of doctors and patients. Beverly Hills based plastic surgeon ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Dental practice ... help patients in need. Most people know that general health emergencies, such as broken ... fewer amount of people know where to turn to during a dental emergency. This ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... Meeting on Lessons from 2004 Tsunami, WASHINGTON, ... psychosocial support responders are meeting to,discuss how disasters ... operations in response to the 2004 tsunami. The ... the American Red Cross. The,American Red Cross oversees ...
... 360m Collaboration with Harvard Medical International Provides ... and Vital Global Health Information, BALTIMORE, Jan. 29 ... the reach of their groundbreaking MEDEX,360m partnership with the ... business and leisure travelers., Like the original MEDEX ...
... 29 /PRNewswire/ - There is new hope for ... called DizzyFIX,patients with vertigo can now treat themselves. ... this visual device helps treat the most common,type ... DizzyFIX has received a number of medical ...
... but unless we harness the powers of our microbial co-habitants ... according to an article in the February 2008 issue of ... organisms that we are, it is easy to view this ... Reay from the University of Edinburgh. In truth of course, ...
... enterprise security, reduces risk and ... ... a global,provider of integrated security, risk and audit management solutions, ... National,Health Service (NHS) has selected its flagship SecureVue(R) platform to,proactively ...
... of Respondents Feel Their Overall Health Affects Their,Recovery ... Mental Health,America of San Diego today released ... overall healthcare in mental health settings from the,perspective ... that although both groups are aware of actions ...
Cached Medicine News:Health News:Global Experts Convene to Discuss Emotional Trauma Caused by Disasters 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:All Star Sales Introduces DizzyFIX a New Treatment for Vertigo and Dizziness 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4
... The MaxxAir ETS™ is a therapeutic, ... of beds., ,INDICATIONS , Prevention ... who are difficult to turn, Large patients ... from a pressure relief surface, Patients whose ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
... A single solution., ,Hill-Rom engineers designed ... safety where its needed. Its long list ... the caregiver and patient from injury, while ... like other TotalCare® beds, but its different ...
Medicine Products: